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Background/introduction
Enhanced sonication (ES) is a newer technique to ablate
symptomatic uterine fibroids. ES uses nearly twice the
amount of energy and is able ablate nearly twice the region
of interest compared to standard sonications. As a result,
more volume of uterine fibroids are able to be treated
within the same amount of time. The objective of the
multi-center trial was to evaluate the clinical efficacy of
enhanced sonication.
Methods
A HIPAA-complaint, IRB-approved prospective single-arm
multi-center trial study of women consecutively evaluated
at seven tertiary care institutions in the United States of
women with symptomatic uterine fibroids was performed.
The study was approved by the institutional review board
at seven tertiary care centers in the United States between
Jan 2010 and Mar-2013. This study was under a post-PMA
approval (open label), single-arm, multicenter study using
the ExAblate 2000 system. Patients were followed for safety
at one week and one month post-treatment. For effective-
ness patients had to consent again to be followed for
3 years. Safety was measured by the incidence, severity and
duration of adverse events; effectiveness was measured by
immediate post-treatment non-perfused ratio, SSS-UFS-
QOL score as compared to baseline and retreatment rate.
We performed paired t-test to evaluate the difference in
UFS-QOL pre and post treatment. Statistics were consid-
ered significant at p = 0.05.
Results and conclusions
Out of 245 screened patients 115 patients underwent 164
treatment sessions (54 patients had a second treatment.)
Of these, 100 agreed to be followed up. Patients were an
average age of 44 and average BMI of 24.9. Of 115,
71 were Caucasian, 13 African American, 8 Asian, and
8 others. 58 patients had a single fibroid, 28 patients had
between 2 to 4 fibroids, and 14 patients had 5 or more
fibroids. The total fibroids volume per patient was in
average 235cc ± 220 (range 10-1300). The average non-
perfused ratio measured immediately after the treatment
was 65% ±23% (range 6%-100%). Baseline SSS for the 100
patients was 66.7±15.7 (range 28-100). At 6 months, in
91 patients who followed up, the SSS decreased to 26.8
±16.2 (range 0-75). There were significant improvements
in the UFS-QOL score overall and the sub-scales includ-
ing symptom severity score (66.4 vs. 25.5, p<0.01), con-
cern (35.7 v. 74.0, p<0.01), activities (37.61 vs. 77.5,
p<0.01), energy (35.7 v 74.4, p<0.01), control (38.2 v.
76.6, p<0.01), self-consciousness (35.5 v 70.6, p<0.01),
sexual function (36.5 v. 73.3, p<0.01) and health-related
quality of life (36.6 v. 75, p<0.01) between baseline and
12 month post treatment, respectively. The number of
patients who underwent alternative treatments at
12 months was 9 (9%). There were no major complica-
tions. Minor complications occurred in <5% of the
patients. Those that lasted longer than 7 days were one
skin burn, patient reported fatigue, one complaint of
abdominal cramping, one of perineal pain, and one with
leg pain for two months.
Conclusion: In this multicenter cohort, sustained
symptom relief was possible up to 12 months with the
addition of enhanced sonicatons to standard sonication
during MR guided HIFU.
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